Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation

Abstract

Cisplatin and gemcitabine is an effective regimen in advanced g<i>BRCA/PALB2</i>+ PDAC. Concurrent veliparib did not improve RR. These data establish cisplatin and gemcitabine as a standard approach in g<i>BRCA</i>/<i>PALB2</i>+ PDAC.